SCHEMBL20127247

SCHEMBL20127247

Cc1ccc(C(=O)O)c2c1OCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
XDH P47989 2/20 0.40
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 3/20 0.37
HSD17B10 Q99714 3/20 0.37
HPGD P15428 2/20 0.37
HTT P42858 1/20 0.37
MAPT P10636 2/20 0.37
PARP1 P09874 1/20 0.37
HAAO P46952 1/20 0.36
SLC22A12 Q96S37 1/20 0.36
FABP4 P15090 1/20 0.35
LMNA P02545 1/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
MEN1 O00255 1/20 0.35
APEX1 P27695 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13850421 0.86 MAOA (0.45) MAOAMAOBXDHKDM4EALDH1A1
SCHEMBL134045 0.85 XDH (0.44) XDHKDM4EALDH1A1HSD17B10HPGD
SCHEMBL20127246 0.85 PARP1 (0.50) MAOAMAOBKDM4EALDH1A1HSD17B10
SCHEMBL28739157 0.80 XDH (0.39) XDHKDM4EALDH1A1HSD17B10HPGD
SCHEMBL4882971 0.79 KDM4E (0.41) XDHKDM4EALDH1A1MAPTPARP1
SCHEMBL5723010 0.79 ALDH1A1 (0.56) XDHKDM4EALDH1A1HSD17B10HPGD
SCHEMBL26550861 0.79 ACE2 (0.41) XDHKDM4EALDH1A1HSD17B10HPGD
SCHEMBL7391414 0.78 RXRA (0.39) MAOAMAOBXDHKDM4EALDH1A1
SCHEMBL6568411 0.77 SMN1; SMN2 (0.38) XDHKDM4EHSD17B10PARP1SLC22A12
SCHEMBL13315458 0.77 SMN1; SMN2 (0.41) KDM4EALDH1A1HSD17B10HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180127420-A1 CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180127420-A1 CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF PDK1, WEE1, DCK MAOA 1258/4885MAOB 648/4885XDH 3181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.